124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study
Year: 2012
Type: conference-abstract
Source: European Urology Supplements
Authors: M. Hussain, P. Corn, D. Michaelson, H. Hammers, J. Alumkal, C. Ryan, J. Bruce, S. Moran, P. Mortimer, S.Y. Lee, D. George
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2328089581